NCT02258009View on ClinicalTrials.gov

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Visual Impairment Due to Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

0.5 mg intravitreal injections

DRUG

Aflibercept

2 mg intravitreal injections

Trial Locations (1)

09113

Novartis Investigative Site, Chemnitz

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY